Ionis Pharmaceuticals reported $112 million in total revenues for Q1 2021. The company has strengthened its balance sheet with a pro forma cash of $2.1 billion. They are on track to achieve their 2021 financial guidance, reflecting investments in Ionis’ wholly owned pipeline.
Total revenues reached $112 million.
Operating expenses were $159 million on a non-GAAP basis and $204 million on a GAAP basis.
Net loss was $45 million on a non-GAAP basis and $90 million on a GAAP basis.
Pro forma cash reached $2.1 billion after reflecting the convertible notes transaction.
Ionis is on track to achieve its 2021 financial guidance and expects R&D revenue to increase in the second half of the year.
Visualization of income flow from segment revenue to net income